BioNTech (BNTX) Competitors $107.06 +0.59 (+0.55%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTX vs. GSK, TAK, ARGX, ONC, TEVA, SMMT, ITCI, GMAB, RDY, and ASNDShould you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. BioNTech vs. Its Competitors GSK Takeda Pharmaceutical argenex BeOne Medicines Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S GSK (NYSE:GSK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership. Do insiders & institutionals hold more shares of GSK or BNTX? 15.7% of GSK shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to GSK or BNTX? In the previous week, BioNTech had 1 more articles in the media than GSK. MarketBeat recorded 21 mentions for BioNTech and 20 mentions for GSK. BioNTech's average media sentiment score of 0.36 beat GSK's score of 0.32 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is GSK or BNTX more profitable? GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets GSK9.89% 48.82% 11.15% BioNTech -27.37%-3.94%-3.41% Which has more risk and volatility, GSK or BNTX? GSK has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Which has higher earnings & valuation, GSK or BNTX? GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGSK$40.10B1.96$3.29B$1.9419.77BioNTech$2.98B8.64-$719.92M-$3.40-31.49 Do analysts recommend GSK or BNTX? GSK presently has a consensus price target of $37.38, suggesting a potential downside of 2.57%. BioNTech has a consensus price target of $137.86, suggesting a potential upside of 28.77%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 1 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.10BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83 SummaryGSK and BioNTech tied by winning 8 of the 16 factors compared between the two stocks. Get BioNTech News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTX vs. The Competition Export to ExcelMetricBioNTechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.74B$2.84B$5.47B$8.89BDividend YieldN/A2.70%5.36%4.13%P/E Ratio-31.4921.0626.4119.70Price / Sales8.64261.28406.20108.23Price / CashN/A41.2925.8827.49Price / Book1.227.187.895.39Net Income-$719.92M-$55.05M$3.15B$248.34M7 Day Performance1.87%-1.36%0.54%0.65%1 Month Performance11.86%5.62%4.77%4.80%1 Year Performance35.81%-0.17%32.14%17.53% BioNTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTXBioNTech2.4886 of 5 stars$107.06+0.6%$137.86+28.8%+32.5%$25.74B$2.98B-31.496,772GSKGSK2.2004 of 5 stars$38.26+0.5%$37.38-2.3%-0.3%$78.33B$40.10B19.7268,629TAKTakeda Pharmaceutical1.3907 of 5 stars$14.72-0.3%N/A+19.5%$46.84B$4.58T66.9149,281ARGXargenex4.3205 of 5 stars$540.76-0.3%$709.18+31.1%+28.2%$33.02B$2.25B33.361,599Trending NewsAnalyst ForecastONCBeOne Medicines3.4639 of 5 stars$257.51+4.2%$319.00+23.9%N/A$28.22B$3.81B-69.2211,000Gap UpTEVATeva Pharmaceutical Industries4.0256 of 5 stars$16.96+0.1%$24.44+44.1%+3.1%$19.45B$16.54B-14.7536,830SMMTSummit Therapeutics2.4882 of 5 stars$20.39-0.8%$35.09+72.1%+172.8%$15.14B$700K-59.97110Analyst UpgradeITCIIntra-Cellular Therapies0.915 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9826 of 5 stars$20.68-2.3%$39.17+89.4%-17.8%$13.26B$3.12B11.752,682Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories2.8095 of 5 stars$15.31+0.5%$16.95+10.7%-1.4%$12.78B$3.81B23.2027,811ASNDAscendis Pharma A/S3.52 of 5 stars$175.78-0.6%$220.67+25.5%+26.6%$10.75B$393.54M-27.991,017Positive News Related Companies and Tools Related Companies GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors Teva Pharmaceutical Industries Competitors Summit Therapeutics Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTX) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BNTX Stock Alerts